"The world is going to want to find a compromise," said David Kelly, chief market strategist at J.P. Morgan Funds.» Read More
Any time military action is a possibility, you absolutely need a gold play, Cramer says. And it doesn't hurt to have some cash on hand either, just in case there's a panic you could profit from.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Iranian mischief is the single most bankable trend in the world, Cramer says. So he’s got a doomsday portfolio for you just in case events take a turn for the worst. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
The chief executive of SAP's TomorrowNow subsidiary, Andrew Nelson, defended the unit's business practices in his first public response to a recent lawsuit from rival Oracle, The Wall Street Journal reported.
Boston Scientific's stock slid on Monday while shares of Abbott Laboratories jumped after a study showed Abbott's drug-coated stent was better at treating clogged heart arteries.
This week's stock rally doesn't mean the market's recent pullback is over, money managers say.
U.S. drugs giant Abbott Laboratories said it would stop launching new medicines in Thailand in protest at the army-backed government's move to override international drug patents.
Drug and medical device maker Abbott Laboratories posted a big fourth-quarter loss due to a charge related to its $3.7 billion purchase of Kos Pharmaceuticals, offsetting stellar sales growth of its medical devices and drugs.
Yahoo and Sun Micro are giving a boost to the Nasdaq this morning but the picture for stocks is mixed as investors await today's earnings reports. Europe and Asian markets were mostly higher, and the dollar is recovering some ground against the euro and sterling, after hitting a 14-year low against the British pound. In addition to Iraq, President Bush's State of the Union puts...
Abbott agreed to sell two diagnostic units to General Electric for $8.13 billion because the business has gotten too big, CEO Miles White told CNBC.
General Electric agreed to buy two of Abbott's diagnostic businesses for $8.13 billion in cash, the companies announced.
It looks like the Journal of the American Medical Association (JAMA) chose fractures as the theme of its new issue. One study shows that taking a popular osteoporosis drug for 5 years and then going off of it for 5 years carries a residual beneficial effect almost as if the patient stayed on the drug for all 10 years. Merck paid for the study of its #3-selling drug, Fosamax. The only exception was a 55% increased risk of fractures of the spine for those who stopped taking Fosamax. Doctors say that means...
Greetings from the Gaithersburg, Maryland Hilton! That's where the FDA is holding the advisory committee meeting on the safety of drug-coated stents. For less high-profile FDA meetings this hotel and the Holiday Inn across the street (the FDA alternates between them) are just fine. But for a big meeting like this one the venue is way too small.
Drug-coated stents that buttress the arteries are safe when used as directed, health advisers say, even though the risks they may pose to the majority of patients with the devices remains an open question
Drug-coated stents that prop open the arteries of about 3 million people in the U.S. don't increase the risk of heart attack or death when used as labeled but may put patients at risk for blood clots, health advisers said Thursday.
Pfizer CEO Jeffrey Kindler expressed disappointment about the failure of the company's new cholesterol drug but said Pfizer plans to continue growing through strategic acquisitions.